GLP-1 drugs linked to 17% drop in worker sick leave, new economic study finds

There are two ways to look at Ozempic in 2026. One: it’s a miracle drug that’s reshaping bodies, reducing heart attacks, and — according to a new economic study covered by CBS News — cutting long-term worker sick leave by 17%. Two: it’s an expensive pharmaceutical dependency that only works while you’re on it, leaving most people back where they started the moment they stop. Both things are true. That’s exactly what makes this conversation so hard to close.

The sick leave finding is the kind of number that makes CFOs sit up straight. Employers have spent years watching obesity-related illness drain productivity budgets. A 17% drop in long-term absences isn’t a rounding error — it’s a structural shift. And now the financial case for covering GLP-1 drugs through employer health plans just got a lot harder to argue against.

The facts:

• Workers using GLP-1 drugs took 17% less long-term sick leave than non-users, defined as illness-related absences exceeding 30 days.
• The reduction in absences translates to salary savings of up to 1.5%, or roughly $866 per worker on average.
• The study was published by the National Bureau of Economic Research and analyzed worker and medication data from Denmark.
• GLP-1 drugs — sold under names including Ozempic and Wegovy — are prescribed for diabetes and obesity and are known to reduce the risk of major cardiovascular events including heart attacks and strokes.
• In original clinical trials, patients who stopped GLP-1 treatment regained most of the weight they had lost, according to NBC News reporting.

Why Is a Danish Study Driving an American Debate?

The research comes with a significant asterisk. Denmark’s sick leave system looks nothing like America’s. Danish employers cover full salaries for illness-related absences up to 30 days. The government steps in after that. In the U.S., many workers don’t get paid sick leave at all, let alone long-term coverage. So when Duke University professor Jonathan Zhang tells CBS News that not having those absences translates to real savings, he’s describing a system with a safety net that most American workers simply don’t have.

That doesn’t make the underlying biology irrelevant. Fewer heart attacks are fewer heart attacks regardless of country code. GLP-1 drugs reduce the risk of major adverse cardiovascular events — that’s settled science. And major cardiac events are exactly the kind of thing that pulls someone out of work for months. The economic signal from Denmark is real. The dollar figure just won’t map cleanly onto an American payroll spreadsheet.

Does the Science Actually Justify the Cost?

GLP-1 drugs work while you take them. That sentence should be printed on every prescription. The clinical trial data is unambiguous: stop the medication, gain back the weight. This isn’t a minor caveat — it’s the entire business model of the drug. Chronic condition, chronic treatment, chronic revenue for Novo Nordisk and Eli Lilly.

Which raises a legitimate question about what employers are actually buying. If covering GLP-1 drugs reduces sick leave while workers are medicated, but coverage lapses when employees leave the company or the plan changes, are you solving the problem or just renting the solution? That tension doesn’t disappear because the sick leave data is compelling. It gets sharper.

There’s also a fascinating adjacent signal worth tracking. As we noted when covering machine learning approaches to Alzheimer’s research, the most promising health interventions increasingly sit at the intersection of biology and long-term systemic commitment. GLP-1 isn’t a one-shot fix. It’s a subscription to better metabolic health, and the moment you cancel, the biology reverts. That’s not a reason to dismiss it — it’s a reason to be honest about what the commitment actually entails.

What Does This Mean for Employers Right Now?

The pressure on companies to cover GLP-1 drugs is already substantial. This study adds economic ammunition to what was mostly a moral and medical argument. A 17% reduction in long-term absences is the kind of ROI metric that gets benefits managers on board. The $866 average salary saving per worker is modest on its own — but multiplied across a workforce of thousands, it starts to look like a defensible line item.

The smarter framing isn’t whether GLP-1 coverage pays for itself. It’s whether employers are willing to treat obesity as the chronic condition it is, with the same commitment they extend to managing diabetes or hypertension. The drugs overlap with all three. The economics are starting to follow the biology, and that’s a pattern worth comparing to how other industries have responded to long-term cost signals — including the slow, structural recalibrations we’ve tracked in areas like carbon emissions trading and enterprise transformation, where short-term cost resistance eventually gave way to policy-driven financial reality.

The next pressure point is whether U.S. insurers follow employers into broader GLP-1 coverage — and whether drug makers price to make that possible, or price to extract maximum margin from a captive market.